Abstract 5324: Circulating tumor DNA detects minimal residual disease and predicts outcomes in esophageal cancer after esophagectomy.

Abstract Background Circulating tumor DNA (ctDNA) monitoring shows promise for detecting minimal residual disease (MRD) and predicting prognosis in various cancers. This study evaluated ctDNA for detecting MRD and predicting outcomes in patients with esophageal cancer (EC) after esophagectomy.MethodsWe conducted a two-step observational study with a retrospective cohort (cohort 1) and a prospective cohort (cohort 2) of 40 EC patients who underwent upfront surgery or neoadjuvant chemotherapy (NAC) followed by esophagectomy. Plasma samples were collected at six time points: pre-therapy, post-NAC, and 1, 3, 6, and 12 months post-surgery. ctDNA was assessed using a 250-gene panel and its association with clinical outcomes was analyzed. Results Tumor-informed ctDNA levels were significantly correlated with tumor stage (P=0.01). Changes in ctDNA levels predicted tumor progression, with an area under the curve of 0.77. Postsurgical ctDNA positivity correlated with reduced recurrence-free survival (RFS) in cohort 1 (n=6, Log-rank P=0.034) and progression-free survival (PFS) in cohort 2 (n=34, Log-rank P=0.025) compared to ctDNA-negative patients. Combined analysis showed that postsurgical ctDNA positivity was associated with shorter PFS (hazard ratio [HR]=12.6, 95% confidence interval [CI]: 1.6-99.0; P=0.002) across all patients (n=40) and shorter RFS (HR=11.1, 95% CI: 1.4-89.0; P=0.006) in those who underwent R0 resection (n=37). ctDNA positivity predicted recurrence at a median of 90 days before radiographic evidence. Conclusions This study showed a strong correlation between ctDNA status and postsurgical prognosis in EC patients. ctDNA assessments can effectively detect MRD and guide postoperative management strategies. Citation Format: Qingjiang Hu, Eiji Oki, Yasue Kimura, Hajime Otsu, Yusuke Yonemura, Koshi Mimori. Circulating tumor DNA detects minimal residual disease and predicts outcomes in esophageal cancer after esophagectomy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5324.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-5324
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 5324: Circulating tumor DNA detects minimal residual disease and predicts outcomes in esophageal cancer after esophagectomy.

Hajime Otsu, Yuji Kimura, Yusuke Yonemura, Q. Hu et al.
Cancer Research
Cancer Genomics and Diagnostics
article

Abstract 5324: Circulating tumor DNA detects minimal residual disease and predicts outcomes in esophageal cancer after esophagectomy.

Hajime Otsu, Yuji Kimura, Yusuke Yonemura, Q. Hu, Eiji Oki, Koshi Mimori
article en

Abstract

Abstract Background Circulating tumor DNA (ctDNA) monitoring shows promise for detecting minimal residual disease (MRD) and predicting prognosis in various cancers. This study evaluated ctDNA for detecting MRD and predicting outcomes in patients with esophageal cancer (EC) after esophagectomy.MethodsWe conducted a two-step observational study with a retrospective cohort (cohort 1) and a prospective cohort (cohort 2) of 40 EC patients who underwent upfront surgery or neoadjuvant chemotherapy (NAC) followed by esophagectomy. Plasma samples were collected at six time points: pre-therapy, post-NAC, and 1, 3, 6, and 12 months post-surgery. ctDNA was assessed using a 250-gene panel and its association with clinical outcomes was analyzed. Results Tumor-informed ctDNA levels were significantly correlated with tumor stage (P=0.01). Changes in ctDNA levels predicted tumor progression, with an area under the curve of 0.77. Postsurgical ctDNA positivity correlated with reduced recurrence-free survival (RFS) in cohort 1 (n=6, Log-rank P=0.034) and progression-free survival (PFS) in cohort 2 (n=34, Log-rank P=0.025) compared to ctDNA-negative patients. Combined analysis showed that postsurgical ctDNA positivity was associated with shorter PFS (hazard ratio [HR]=12.6, 95% confidence interval [CI]: 1.6-99.0; P=0.002) across all patients (n=40) and shorter RFS (HR=11.1, 95% CI: 1.4-89.0; P=0.006) in those who underwent R0 resection (n=37). ctDNA positivity predicted recurrence at a median of 90 days before radiographic evidence. Conclusions This study showed a strong correlation between ctDNA status and postsurgical prognosis in EC patients. ctDNA assessments can effectively detect MRD and guide postoperative management strategies. Citation Format: Qingjiang Hu, Eiji Oki, Yasue Kimura, Hajime Otsu, Yusuke Yonemura, Koshi Mimori. Circulating tumor DNA detects minimal residual disease and predicts outcomes in esophageal cancer after esophagectomy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5324.

Cancer ResearchVol. 86(7_Supplement)
Fukuoka University Hospital (JP), National Hospital Organization Kyushu Cancer Center (JP), Kyushu University Hospital (JP), Kyushu University Beppu Hospital (JP)
Good health and well-being
Openalex Percentile: Top 9%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.